Aliva Prity Minz
NIH Clinical Cente, Institute of Life Sciences, National Institute of Technology Rourkela, Odisha University of Agriculture and Technology
0000-0002-9878-1743
About
Dr. Aliva Prity Minz is a cancer immunologist specializing in T-cell, macrophage, and tumor microenvironment (TME) biology. She earned her Ph.D. from the Institute of Life Sciences, Bhubaneswar, India, where she studied how the chemotherapeutic agent gemcitabine reshapes non-immune cells (Cancer associated Fibroblast cells) within the pancreatic tumor microenvironment. Her work uncovered a JAK/STAT-dependent mechanism of chemotherapy-induced immune evasion and identified a statin-based combination strategy to overcome it. She also demonstrated that gemcitabine polarizes M0 and M2 macrophages toward an antitumorigenic phenotype, enhancing their cytotoxic activity against cancer cells.
She completed her 2 year postdoctoral training at the National Institutes of Health (NIH), USA, where she developed a novel long-term T cell–organoid co-culture platform and applied TCR sequencing to identify tumor-reactive T-cell receptor clonotypes for engineered adoptive cell therapies. Her work has also characterized the natural enrichment of cytotoxic T-cell subsets in this culture system, with implications for allogeneic, off-the-shelf cell therapies.
Research Interests: Tumor microenvironment (TME) immunology, TCR-engineered and CAR-T cell therapy, macrophage polarization and reprogramming in cancer, immune evasion mechanisms (PD-L1/PD-L2 signaling), patient-derived organoid systems, and cytotoxic T-cell biology for adoptive cell therapy.
Employment
-
NIH Clinical Cente Postdoc2023 - 2025
Education
-
Institute of Life Sciences Ph.D2016 - 2023
-
National Institute of Technology Rourkela M.Sc? - 2015
-
Odisha University of Agriculture and Technology B.Sc? - 2013
Projects & Funding
Projects & funding information is unavailable.
Publications (15)
- Immunomodulatory activity of bamboo biosilica from Dendrocalamus longispathus Kurz. - Metabolomics integrated network pharmacology approach. Save
- Whole Genome Mining and Characterization of a New Probiotic Strain Levilactobacillus brevis ILSH3 from Handia: An Ethnic Fermented Beverage of Odisha, India. Save
- Statins abrogate gemcitabine-induced PD-L1 expression in pancreatic cancer-associated fibroblasts and cancer cells with improved therapeutic outcome Save
- Biochemical, functional and genomic characterization of a new probiotic Ligilactobacillus salivarius F14 from the gut of tribes of Odisha. Save
- Gemcitabine induces polarization of mouse peritoneal macrophages towards M1-like and confers antitumor property by inducing ROS production Save
- SMRT and NCoR1 fine-tune inflammatory versus tolerogenic balance in dendritic cells by differentially regulating STAT3 signaling. Save
- Fluvastatin sensitizes pancreatic cancer cells toward radiation therapy and suppresses radiation- and/or TGF-β-induced tumor-associated fibrosis. Save
- Fusogenic Viral Protein-Based Near-Infrared Active Nanocarriers for Biomedical Imaging. Save
- Tissue Distribution of ACE2 Protein in Syrian Golden Hamster (Mesocricetus auratus) and Its Possible Implications in SARS-CoV-2 Related Studies. Save
- Analysis of Indian SARS-CoV-2 Genomes Reveals Prevalence of D614G Mutation in Spike Protein Predicting an Increase in Interaction With TMPRSS2 and Virus Infectivity. Save